Business Wire

Textron Aviation Defense and Thai Aviation Industries Sign Agreement to Support Royal Thai Air Force

19.6.2025 08:30:00 CEST | Business Wire | Press release

Share

During the Paris Air Show, Textron Aviation Defense LLC., a Textron Inc. (NYSE: TXT) company, and Thai Aviation Industries Co., Ltd. signed a Memorandum of Agreement to work together on a sustainment program for the Royal Thai Air Force (RTAF). This program will support RTAF's fleets of Beechcraft T-6TH and AT-6TH aircraft.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618711147/en/

Textron Aviation Defense LLC. and Thai Aviation Industries Co., Ltd. sign a Memorandum of Agreement to sustain Beechcraft T-6TH trainer and AT-6TH light attack aircraft for the Royal Thai Air Force (RTAF)

The Beechcraft T-6TH trainer and AT-6TH light attack aircraft are designed and manufactured by Textron Aviation Defense LLC., a wholly owned subsidiary of Textron Aviation Inc.

Textron Aviation Defense, based in Wichita, Kansas, USA, is the original equipment manufacturer (OEM) for these aircraft. Thai Aviation Industries, located in Bangkok, Thailand, is the prime contractor for this program and has a long history of providing support for RTAF.

“The Beechcraft T-6TH and AT-6TH aircraft strengthen the mutual defense cooperation and relationship between the U.S. and Thailand,” said Tom Webster, vice president, Defense Sales. “This agreement with Thai Aviation Industries ensures the highest level of sustainment support for the RTAF and is an important element of our commitment to the growth of Thailand’s aerospace industry.”

The agreement highlights the strengths of both companies. Textron Aviation Defense brings its expertise as the aircraft's OEM, while Thai Aviation Industries offers its unique position and experience in Thailand.

This collaboration aims to provide long-term support and sustainment for RTAF's aircraft, ensuring a high level of readiness for training and light attack missions. Both companies are committed to working together to deliver the best possible service to RTAF.

About the Beechcraft T-6 Texan II

The Beechcraft T-6 Texan II is the world’s premier military flight trainer. The aircraft’s low acquisition, operating and sustainment costs enable global air forces to fast-track pilot production. With an installed base that more than quadruples its closest competitor, the family of Beechcraft T-6 Texan II aircraft has been the world’s number one Integrated Training System (ITS) for more than 20 years. The Beechcraft T-6 Texan II capitalizes on an active production line with an industry-leading Manufacturing Readiness Level (MRL) rating of 10 as well as a proven supply chain and the affordability of 85 percent parts commonality with the Beechcraft AT-6 Wolverine. To date, the global fleet of more than 1,000 Beechcraft T-6 Texan II aircraft has surpassed 5 million flight hours across 14 nations and two NATO flight schools.

A vital asset, the T-6 empowers global pilot training across the North Atlantic Treaty Organization (NATO) Flight Training program in Canada, the Euro NATO Joint Jet Pilot Training Program (ENJJPT) at Sheppard AFB, Texas and the U.S. Air Force Aviation Leadership Program as well as the U.S. Air Force, Navy, Marine Corps, Army and Coast Guard, the Hellenic Air Force, the Argentine Air Force, the Israeli Air Force, the Royal Air Force, the Iraqi Air Force, the Royal Canadian Air Force, Mexican Navy, the Mexican Air Force, the Royal Moroccan Air Force, the Colombian Air Force, the Royal New Zealand Air Force, the Royal Thai Air Force, Tunisian Air Force and the Vietnam Air Defense Air Force.

About the Beechcraft AT-6 Wolverine

Purpose-built for light attack, counter-insurgency and Countering Violent Extremist Organizations (C-VEO), the high performance, low risk Beechcraft AT-6 Wolverine delivers affordable precision and endurance across operations in austere environments. The aircraft empowers operators with Next Gen Intelligence, Surveillance and Reconnaissance (ISR), the industry's best loitering close air support / precision strike capability, the ability to maintain pressure on targets, and reliable networked battlespace communications and video, linking every sensor to every operator — anytime, anywhere.

The U.S. Air Force completed the aircraft's military type certification and acquired two Beechcraft AT-6E Wolverine in 2020. The Royal Thai Air Force, a key U.S. security ally and operator of one of the most advanced air forces in Asia Pacific, followed in 2021, selecting the Beechcraft AT-6TH Wolverine to support their 41st Wing light attack operations at Chiang Mai Air Base.

About Textron Aviation Defense LLC

With a legacy of thousands of proven Beechcraft and Cessna Integrated Training Systems produced and missionized in America’s Heartland since WWII, military customers turn to Textron Aviation Defense when they need airborne solutions for their critical missions. Provider of the world’s foremost military flight trainer, Textron Aviation Defense equips militaries worldwide and leads in low acquisition, sustainment and training costs. The Beechcraft T-6 Texan II fleet of more than 1,000 aircraft has logged more than 5 million hours across two NATO military flight schools and fourteen countries since 2001. Textron Aviation Defense is a subsidiary of Textron Aviation Inc.

About Textron Aviation

We inspire the journey of flight. For more than 95 years, Textron Aviation has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops and high-performance pistons, to special missions, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable, productive and flexible flight.

For more information, visit www.txtav.com| specialmissions.txtav.com| defense.txtav.com| scorpion.txtav.com.

About Textron Inc.

Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, and Textron Systems.

For more information, visit: www.textron.com.

Certain statements in this press release may project revenues or describe strategies, goals, outlook or other non-historical matters; these forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update them. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements.

About Thai Aviation Industries Co.,Ltd.

Thai Aviation Industries Co.,Ltd. (TAI) was established by the policy of the Government of Thailand and the Royal Thai Air Force to carry out aircraft maintenance for government agencies and to expand Thailand’s aviation maintenance capabilities to be an international standard aircraft maintenance center. TAI is an approved Thai MRO company that received the privilege from the Public Procurement and Supplies Administrative Act for maintenance support to all states Aircraft.

TAI has played a significant role in the MRO service including the logistics support to all military and commercial aircraft in Thailand for more than 20 years. TAI maintains capabilities in varies Aircraft type such as F-16A/B, C-130H, T-6C, Alpha Jet, Saab 340, BT-67, ATR72-500, S-92A, Cessna 150/152/172/182/208, Bell 121/412 Series, Airbus A320 Series, Boeing B737 Series, Airbus Helicopters (H125/H145/H155/H175), etc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250618711147/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye